David McIntyre's most recent trade in Inhibikase Therapeutics Inc was a trade of 1,775,539 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | David McIntyre | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2025 | 1,775,539 | 1,775,539 | - | - | Stock Option (Right to Buy) | |
| AVITA Medical Inc | David McIntyre | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 22.70 per share. | 16 Jul 2020 | 393 | 893 | - | 22.7 | 8,921 | Common Stock |
| AVITA Medical Inc | David McIntyre | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 23.85 per share. | 16 Jul 2020 | 300 | 500 | - | 23.9 | 7,155 | Common Stock |